In a sample of 128 women with stage IB/II grade 3 endometrioid carcinoma, adjuvant vaginal brachytherapy/whole pelvic radiotherapy improved disease‐specific survival and overall survival in MMR deficient but not in MMR proficient cases. This evidence concerns the gene MRC1 and endometrioid adenocarcinoma.